The table below shows Akebia Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$21.21M
-$13.59M
-$19.43M
-$17.54M
-$21.62M
-$70.75M
Capital expenditure
$62.00K
$18.00K
$0.00
$0.00
$114.00K
$59.00K
Investing cash flow
-$62.00K
$154.00K
$0.00
$0.00
-$114.00K
$19.94M
Dividends paid
-
-
-
-
AKBA operating cash flow (10-K history)
Akebia Therapeutics, Inc. reported operating cash flow of $67.99M for fiscal year 2025. That is up 267.2% from -$40.66M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $57.91M (FY 2016) to $67.99M. Figures come from the company's audited annual reports as filed with the SEC.